Page 9 - Opgen News Today

ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power...

ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, "OpGen" or "the Company"), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to

Completes first two commercial customer installations for Acuitas AMR Gene PanelOpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG...

Investment analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Get Rating) in a report released on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock. A number of other research firms have also issued reports on OPGN. Alliance Global Partners lowered OpGen to a “neutral” rating in a […]

Total Q2 2022 revenues of $1.0 million with product sales a key growth driverFirst two commercial customer contracts for Acuitas AMR Gene Panel signed in...

Precigen, Inc. (NASDAQ:PGEN – Get Rating) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.30 and traded as low as $1.23. Precigen shares last traded at $1.35, with a volume of 2,668,070 shares changing hands. Separately, HC Wainwright reissued a […]

Exclusive distribution agreement for initial term of three yearsLeader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term...

Equities research analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to report sales of $46.74 million for the current quarter, Zacks reports. Three analysts have made estimates for Precigen’s earnings, with estimates ranging from $22.60 million to $85.00 million. Precigen reported sales of $33.58 million during the same quarter last year, which would suggest a […]

Analysts expect Precigen, Inc. (NYSE:PGEN – Get Rating) to announce earnings per share (EPS) of ($0.01) for the current quarter, Zacks reports. Three analysts have issued estimates for Precigen’s earnings, with the lowest EPS estimate coming in at ($0.14) and the highest estimate coming in at $0.19. Precigen reported earnings of ($0.10) per share during […]

OpGen (NASDAQ:OPGN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic […]